La bourse ferme dans 1 h 37 min

Nicox S.A. (COX.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
4,4200-0,1750 (-3,81 %)
À partir de 3:38PM CET. Marché ouvert.
Plein écran
Clôture précédente4,5950
Ouverture4,6000
Offre0,0000 x 0
Vente0,0000 x 0
Var. jour4,4150 - 4,6300
Sur 52 semaines2,5300 - 6,2700
Volume199 684
Volume moyen312 372
Cap. boursière163,674M
Bêta (mensuel sur 5 ans)1,53
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-0,6250
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 an16,30
  • Globe Newswire

    Nicox : Initiation d’une couverture analyste par Edison Investment Research

    Communiqué de presse Nicox : Initiation d’une couverture analyste par Edison Investment Research 22 janvier 2021 – diffusion à 7h30 Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, annonce aujourd’hui l’initiation d’une couverture analyste de Nicox par Edison, une société de recherche en matière d'investissement et de conseil disposant d'une plateforme de recherche de valeurs de renommée mondiale et d'une expertise internationale approfondie dans le domaine de la santé. L’analyse financière d'Edison publiée le 21 janvier 2021 est accessible sur le site internet d'Edison https://www.edisongroup.com/publication/focus-on-sight/28664. Le titre Nicox est également suivi par Bryan, Garnier & Co et Kepler Cheuvreux en France, et H.C Wainwright & Co., Oppenheimer & Co. Inc. ainsi que Cantor Fitzgerald aux Etats-Unis. Michele Garufi, Président Directeur Général de Nicox, donnera une présentation à la conférence Edison Open House Global Healthcare 2021 qui se tiendra sous forme virtuelle du 26 au 28 janvier 2021. Un enregistrement vidéo de la présentation sera disponible sur demande en cliquant sur ce lien et accessible sur le site internet de la Société (www.nicox.com) à la rubrique “Présentations & Evènements”. A propos de NicoxNicox S.A. est une société internationale spécialisée en ophtalmologie développant des solutions innovantes visant au maintien de la vision et à l’amélioration de la santé oculaire. Le principal programme en développement clinique de la Société est le NCX 470, un nouvel analogue de prostaglandine donneur d’oxyde nitrique, pour la réduction de la pression intraoculaire chez les patients atteints de glaucome. Nicox développe également le NCX 4251, une formulation brevetée de la fluticasone, pour les épisodes aigus de blépharite. Nicox génère des revenus provenant de VYZULTA® dans le glaucome, licencié exclusivement au niveau mondial à Bausch + Lomb et de ZERVIATE™ dans la conjonctivite allergique. ZERVIATE est licencié dans plusieurs territoires, notamment à Eyevance Pharmaceuticals, LLC, pour les Etats-Unis et à Ocumension Therapeutics pour les marchés chinois et de la grande majorité d’Asie du Sud-Est. Nicox, dont le siège social est à Sophia Antipolis (France), est cotée sur Euronext Paris (Compartiment B : Mid Caps ; Mnémo : COX) et fait partie des indices CAC Healthcare, CAC Pharma & Bio et Next 150. Pour plus d’informations sur Nicox, ses produits ou son portefeuille : www.nicox.com.Couverture par les analystesBryan, Garnier & Co Hugo Solvet Paris, FranceCantor Fitzgerald Lousie Chen New York, Etats-Unis Edison Pooya Hemami Londres, Royaume-UniH.C. Wainwright & Co Yi Chen New York, Etats-Unis.Kepler Cheuvreux Damien Choplain Paris, France Oppenheimer & Co Hartaj Singh New York, Etats-Unis Les positions exprimées par les analystes dans leurs notes sur Nicox leurs sont propres et ne reflètent pas celles de la Société. De plus, les informations contenues dans leurs rapports peuvent ne pas être correctes ou à jour. Nicox s’affranchit de toute obligation de corriger ou de mettre à jour les informations contenues dans les rapports des analystes.ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Relations Investisseurs et MediaEtats-Unis & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853mchang@lifesciadvisors.comRelations MediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 sophie@lifesciadvisors.comEnoncés prospectifs Les informations contenues dans le présent document pourront être modifiées sans préavis. Ces informations contiennent des déclarations prospectives, lesquelles ne constituent pas des garanties quant aux performances futures. Ces déclarations sont fondées sur les anticipations et les convictions actuelles de l’équipe dirigeante de Nicox S.A. et sont tributaires d’un certain nombre de facteurs et d’incertitudes en conséquence desquels les résultats réels pourraient sensiblement différer de ceux décrits dans les déclarations prospectives. Nicox S.A. et ses affiliés, administrateurs, dirigeants, employés, conseils ou mandataires ne prennent pas l’engagement et ne sont pas tenus de publier des mises à jour d’une quelconque déclaration prospective ou de réviser une quelconque déclaration prospective. Les facteurs de risque susceptibles d’avoir des répercussions significatives sur l’activité de Nicox S.A. sont exposés au chapitre 3 du Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019 qui a été déposé auprès de l'AMF le 6 mars 2020 et qui est disponible sur le site de Nicox (www.nicox.com) et repris au chapitre 4 du rapport semestriel financier au 30 juin 2020 est également disponible sur le site de Nicox.Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Pièce jointe FR _ Edison Nicox Initiation PR_20210122_F1

  • Globe Newswire

    Nicox Analyst Coverage Initiated by Edison Investment Research

    Press ReleaseNicox Analyst Coverage Initiated by Edison Investment Research January 22, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Edison, an investment research and advisory company with a world-renowned equity research platform and deep international healthcare expertise, has initiated equity research coverage of Nicox. The financial report by Edison, released on January 21, 2021, is available on the Edison website https://www.edisongroup.com/publication/focus-on-sight/28664. Nicox is also covered by Bryan, Garnier & Co. and Kepler Cheuvreux in France, and H.C Wainwright & Co., Oppenheimer & Co. Inc. and Cantor Fitzgerald in the U.S. Michele Garufi, Chairman and CEO of Nicox, will present at the Edison Open House Global Healthcare Conference 2021 being held virtually on January 26-28, 2021. The video webcast of Nicox's presentation will be available on-demand by clicking here and accessible on Nicox's website (www.nicox.com) in the “Presentations & Events” section. About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.Edison Pooya Hemami London, U.K.H.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Damien Choplain Paris, FranceOppenheimer & Co Hartaj Singh New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853mchang@lifesciadvisors.comMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 sophie@lifesciadvisors.comForward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website..Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Attachment EN_Edison Nicox Initiation PR_20210122_F1

  • Globe Newswire

    Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights

    Press ReleaseNicox Provides Fourth Quarter 2020 Business Update and Financial Highlights Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitisPhase 3 clinical trial of ZERVIATE™ in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S. prescriptions for VYZULTA® in Q4 2020 increased by 29% over Q4 2019, and for ZERVIATETM by 56% over Q3 2020Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020 January 20, 2021 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q4 2020 for Nicox SA and its subsidiaries (the “Nicox Group”), as well as key expected value-inflection milestones in 2021. Key Expected Milestones NCX 470 first Phase 3 trial, Mont Blanc: Nicox’s lead clinical product candidate, NCX 470 is a novel nitric oxide (NO) donating prostaglandin analog. Mont Blanc is a 3-month safety and efficacy trial evaluating NCX 470 ophthalmic solution, 0.1%, against latanoprost ophthalmic solution, 0.005%, for lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Top-line results are now prudently expected in H1 2022, instead of Q4 2021, given probable delays in recruitment due to COVID-19. NCX 4251 Phase 2b trial, Mississippi: NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals. Mississippi is evaluating once-daily dosing NCX 4251 0.1% versus placebo for the treatment of acute exacerbations of blepharitis. Top-line results are currently expected in Q4 2021. We expect to enter into additional agreements for ZERVIATETM (cetirizine ophthalmic solution), 0.24%, further enlarging the licensed territories and increasing potential future revenue. Fourth Quarter 2020 and Recent Operational Highlights Innovative pipeline The second Phase 3 trial of NCX 470, Denali, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, was initiated in the U.S. on November 9, 2020. Denali is a 3-month trial evaluating the safety and efficacy of NCX 470 ophthalmic solution, 0.1% versus latanoprost ophthalmic solution, 0.005% and will also include a long-term safety extension. The trial is financed jointly and in equal parts by Nicox and its Chinese partner Ocumension. Top-line results are currently expected in Q4 2022.The Phase 2b trial of NCX 4251, Mississippi, for the treatment of acute exacerbations of blepharitis was initiated in the U.S. on December 14, 2020. Top-line results are currently expected in Q4 2021.A Phase 3 trial of ZERVIATETM (cetirizine ophthalmic solution), 0.24%, for the treatment of ocular itching associated with allergic conjunctivitis, conducted and financed by Nicox’s Chinese partner Ocumension, was initiated in China in December 2020. This trial will support the submission of a Chinese New Drug Application. NCX 1728 was selected as the first development candidate in a new class of agents for IOP lowering where NO-mediated effects are enhanced by concomitant action of phosphodiesterase-5 (PDE5) inhibition within the same molecule. Further optimization of the ophthalmic formulations of NCX 1728 will continue prior to initiating formal pre-Investigational New Drug (IND) tests required for the filing of an IND application. Commercial products The total number of prescriptions1 for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, in the U.S. increased by 29% in the fourth quarter of 2020 compared to the fourth quarter of 2019 and by 16% compared to the third quarter of 2020 despite the challenging situation due to the COVID-19 pandemic. Along with the U.S., Canada and Argentina, VYZULTA has also been launched by Nicox’s global partner Bausch + Lomb in Mexico and was recently approved in Colombia.ZERVIATETM (cetirizine ophthalmic solution), 0.24%, U.S. prescriptions2 increased by 56% in the fourth quarter of 2020 over the third quarter of 2020. ZERVIATE has been commercialized in the U.S. since March 2020 by Nicox’s U.S. partner Eyevance Pharmaceuticals, which was acquired in September 2020 by Santen Holdings U.S. Inc., a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd of Japan, for $225 million. Corporate The Company completed a €15 million private placement with investors including long-term shareholder HBM Healthcare Investments alongside specialist institutional investors in the U.S. and Europe.The European Patent Office granted a formulation patent for NCX 470, extending the European exclusivity to 2039. The equivalent U.S. patent has already been granted, and NCX 470 is also covered by granted composition of matter patents.Fera Pharmaceuticals, Nicox’s partner for naproxcinod, will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection. Fera plans to initiate pre-clinical proof-of-concept studies in models of COVID-19 infection in early 2021.Ora and Nicox have agreed to terminate their license agreement for the development of NCX 4280 targeting lid swelling, or morning eye congestion. All rights to NCX 4280 will return to Nicox and there are no current plans to continue the development. We continue to closely watch the spread and impact of the COVID-19 pandemic and we will provide an update of any delays. Fourth Quarter 2020 Financial Highlights As of December 31, 2020, the Nicox Group had cash and cash equivalents of €47.8 million as compared with €28.0 million at December 31, 2019 and €42.2 million at September 30, 2020. Net revenue3 for the fourth quarter of 2020 was €5.8 million (consisting of €0.3 million of royalty payments and €5.5 million of license payments recognized from €14.0 million paid by Ocumension in March 2020 and initially recorded as prepaid income pursuant to accounting principles). Net revenue3 for the fourth quarter of 2019 was €0.6 million and consisted entirely of royalty payments. Net revenue3 for the full year 2020 was €8.9 million (€2.4 million in net royalties, €6.5 million in license payments), compared to €6.9 million (€2.1 million in net royalties, €4.8 million in license payments) for the full year 2019. As of December 31, 2020, the Nicox Group had financial debt of €18.4 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €2 million credit agreement with Société Générale and LCL, guaranteed by the French State, and granted in August 2020 in the context of the COVID-19 pandemic. Only the figure related to the cash position of the Nicox Group as of December 31, 2019 is audited; all other figures of this press release are non-audited. Notes Bloomberg data, comparing the period of the weeks ending October 2, 2020 to January 1, 2021 with the periods of the weeks ending July 3, 2020 to September 25, 2020 and October 4, 2019 to December 27, 2019Bloomberg data, comparing the period of the weeks ending October 2, 2020 to January 1, 2021 with the period of the weeks ending July 3, 2020 to September 25, 2020Net revenue consists of revenue from collaborations less royalty payments, which corresponds to Net profit in the consolidated statements of profit or loss About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.H.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Damien Choplain Paris, FranceOppenheimer & Co Hartaj Singh New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853mchang@lifesciadvisors.comMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 sophie@lifesciadvisors.com Forward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website.Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Attachment EN_Q4 2020 Results PR_20210120_F1